Lundbeck adds "blockbuster" to $ 2 billion purchase from Aulder
[ad_1] The Danish biopharmaceutical company Lundbeck has announced its intention to launch eptinezumab, a potentially dangerous biological agent for migraine, early next year after agreeing to buy Alder BioPharmaceuticals. The cash transaction, which is expected to be finalized in the fourth quarter of 2019, stands at $ 1.95 billion (1.78 billion euros) and fits into … Read more